Jiangsu Beagle Biomed Co., Ltd. (hereinafter referred to as ‘Beagle Biomed’) and EV(Shanghai) Biomed Co., Ltd. (hereinafter referred to as ‘EV Biomed’) announced merger and reorganization in August 2022, Carrier (Suzhou) Biomed Co., Ltd. was officially founded and settled in the Artificial Intelligence Industrial Park of Suzhou Industrial Park, powering the original R&D of exosome technology.
Founded in March 2018, Beagle Biomed has owned the exclusive authorization of Professor Andrew Hill, the second chairman of ISEV (International Society for Extracellular Vesicles) and vice president of Victoria University in China for neurodegenerative disease diagnosis IP, and is committed to the R&D of early diagnosis and screening of neurodegenerative diseases based on blood exosome biomarkers. EV Biomed was co-founded by Prof. Hang Yin and Dr. Frederick Li in March 2019, committed to the development and clinical application research of innovative exosome specific capture probe kit. Beagle Biomed and EV Biomed announced the merger and reorganization in August 2022, and a new company, Carrier Biomed, under Suzhou’s project policy of ‘One case, one method’, was officially founded in the Artificial Intelligence Industrial Park in Suzhou Industrial Park, Suzhou City, Jiangsu Province of China.
Along with this merger and reorganization, the capital advantages, industrial advantages and human resource advantages of the two companies have been further integrated, and the “1+1>2” empowerment has been upgraded. At present, Carrier Biomed has developed an exosome separation platform with independent intellectual property rights and multiple pipelines based on thousands of large-scale multicenter clinical studies, including early blood diagnosis of neurodegenerative diseases, early diagnosis of tumors and dynamic monitoring of terminal treatment; More than 2700 square meters of exosome technology R&D and an exosome production plant of Class 100 with international standards are expected to be commissioned in December 2022.
Carrier Biomed currently is in a stage of rapid development with the financing of over a hundred million yuan. Carrier Biomed in the future will continuously focus on clinical value, lead the industry innovation, and be committed to the highest standard in the industry.